Dr. Scott Kollins is a tenured Professor and Vice-Chair for Research Strategy and Development in the Department of Psychiatry and Behavioral Sciences at the Duke University School of Medicine. Scott is the Global Lead for ADHD and Substance Use Disorders at the Duke Clinical Research Institute (DCRI). He is also the Director of the Duke ADHD Program. He received his undergraduate degree in psychology from Duke University in 1992 and earned his Master’s and Doctorate degrees in Clinical Psychology from Auburn University in 1995 and 1997, respectively. Scott completed his clinical internship at the University of Mississippi Medical Center, where he served as Chief Intern. Following internship, he joined the faculty of the Department of Psychology at Western Michigan University for three years, before joining the Duke faculty in 2000. Scott has published more than 130 scientific papers in peer-reviewed journals. Over the past 15 years, Scott’s research has been supported by 7 different federal agencies, including NICHD, NIDA, NIMH, NIEHS, NINDS, FDA, and EPA. In 2016, Scott received nearly $2 million in NIH funding for his work, ranking him among the Top 100 Psychiatry faculty members in the US. He currently holds a K24 career development award from NIDA. Scott has also served as PI on more than 40 industry-funded clinical trials and is a consultant to a number of pharmaceutical companies in the area of ADHD clinical psychopharmacology. Scott is an elected member of both the College on Problems of Drug Dependence and the American College of Neuropsychopharmacology and is a Fellow of the American Psychological Association Division 28 (Psychopharmacology and Substance Abuse). He has served as a standing member of the Child Psychopathology and Developmental Disabilities study section and also served as an ad-hoc reviewer for 10 additional NIH study sections and 7 international granting agencies. He is an Associate Editor for the Journal of Attention Disorders and has reviewed for more than 50 different peer-reviewed journals. Scott is a licensed clinical psychologist and maintains a practice through the ADHD Program’s outpatient clinic. Scott’s research interests are in the areas of psychopharmacology and the intersection of ADHD and substance abuse, particularly cigarette smoking.
"I Use Weed for My ADHD": A Qualitative Analysis of Online Forum Discussions on Cannabis Use and ADHD.
A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder.
A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).
A double-blind, placebo-controlled study of atomoxetine in young children with ADHD.
A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder.
A pilot study of atomoxetine in young children with attention-deficit/hyperactivity disorder.
A pilot study of lis-dexamfetamine dimesylate (LDX/SPD489) to facilitate smoking cessation in nicotine-dependent adults with ADHD.
A pilot study of methylphenidate preference assessment in children diagnosed with attention-deficit/hyperactivity disorder.
A Pilot Trial of Mindfulness Meditation Training for ADHD in Adulthood: Impact on Core Symptoms, Executive Functioning, and Emotion Dysregulation.
A preliminary analysis of interactions between genotype, retrospective ADHD symptoms, and initial reactions to smoking in a sample of young adults.